Sphingosine 1-Phosphate (S1P) Receptor Modulators (UC)

Sphingosine 1-phosphate (S1P) receptor modulators are primarily indicated as maintenance therapy for which of the following conditions? A. Mild Crohn’s Disease B. Moderate-to-severe Ulcerative Colitis C. Chronic Irritable Bowel Syndrome (IBS) D. Acute Diverticulitis

B. Moderate-to-severe Ulcerative Colitis

A patient is being screened for S1P receptor modulator therapy. Which of the following medical histories would present a contraindication for this class of medication? (Select all that apply) A. History of Mobitz Type II second-degree heart block B. Recent myocardial infarction (within the last 6 months) C. New York Heart Association (NYHA) Class III/IV heart failure D. History of seasonal allergic rhinitis

A. History of Mobitz Type II second-degree heart block, B. Recent myocardial infarction (within the last 6 months), C. New York Heart Association (NYHA) Class III/IV heart failure

What is the minimum recommended time interval that must be maintained between the administration of a live vaccine and the initiation of S1P receptor modulator therapy? A. 1 week B. 2 weeks C. 1 month D. 3 months

C. 1 month

A female patient of childbearing potential is prescribed Etrasimod. According to safety guidelines, how long must she continue to use effective contraception after her final dose of the medication? A. 1 week B. 2 weeks C. 1 month D. 3 months

A. 1 week

Regarding Ozanimod therapy, which of the following statements is true for women capable of childbearing? A. Contraception is only required during the first month of therapy. B. Contraception should be used during treatment and for 1 week after the last dose. C. Contraception should be used during treatment and for 1 month after the last dose. D. Contraception should be used during treatment and for 3 months after the last dose.

D. Contraception should be used during treatment and for 3 months after the last dose.